Novartis AG (NOVN) PT Set at CHF 90 by HSBC Holdings plc
Novartis AG (VTX:NOVN) has been given a CHF 90 price objective by stock analysts at HSBC Holdings plc in a report released on Thursday. The firm currently has a “buy” rating on the stock.
Several other research firms also recently weighed in on NOVN. Goldman Sachs Group, Inc. (The) set a CHF 80 price objective on shares of Novartis AG and gave the stock a “neutral” rating in a report on Tuesday, August 8th. J P Morgan Chase & Co set a CHF 70 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research report on Saturday, May 20th. Kepler Capital Markets set a CHF 87 price target on shares of Novartis AG and gave the stock a “buy” rating in a research report on Monday, August 28th. Jefferies Group LLC set a CHF 100 price objective on Novartis AG and gave the stock a “buy” rating in a report on Monday, May 29th. Finally, UBS AG set a CHF 78 price objective on Novartis AG and gave the stock a “neutral” rating in a report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. Novartis AG has an average rating of “Hold” and a consensus target price of CHF 85.
Shares of Novartis AG (VTX:NOVN) opened at 80.15 on Thursday. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 84.35. The firm has a market cap of CHK 187.78 billion and a PE ratio of 29.26. The company’s 50-day moving average is CHK 80.92 and its 200-day moving average is CHK 78.33.
About Novartis AG
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.